Approved Pulmonary Hypertension Drugs Reduce Hospitalizations

More than half of pulmonary hypertension (PH) patients are hospitalized within their first year of diagnosis, usually due to complications from the disease. In this video from AJMCtv, Dr. Charles Burger from the Mayo Clinic talks about three separate clinical trials for pulmonary hypertension medications which saw a reduction in the number of patients needing hospital care.

Discover how heart failure can cause pulmonary hypertension.

Burger discusses the clinical trial results for selexipag, macitenatan, and a combination of tadalafil and ambrisentan and explains how all three showed promising signs that patients were less likely to need emergency hospitalization and showed signs of improvement.

Macitentan reduces pulmonary hypertension severity by halting associated metabolic changes. Find out more.

Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.